PARIS & EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–ACIST Medical Systems Inc., a Bracco Group Company, today announced results from the ACIST-FFR Study (Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve measurement) demonstrating the consistent and correlative performance of the Navvus® MicroCatheter compared to standard pressure wire systems. ACIST-FFR is […]
Coronary/Structural Heart
Elixir Medical Announces Outstanding 5-Year Clinical Data For CE Mark-Approved Desolve Novolimus Eluting Bioresorbable Coronary Scaffold System
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced excellent 5-year clinical data from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System. Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, […]
What is the Significance of Lipid-rich Plaque and Should it Influence Targets for PCI?
By Ken Dropiewski Lipid-rich plaque in non-culprit lesions has long been associated with subsequent cardiac events. Unlike culprit lesions, known to be the cause of AMI, non-culprit lesions including those with a core of lipid-rich plaque are often left untreated during an intervention. The fact that these lesions may lead […]
Shockwave Medical Snags CE Mark for Coronary Lithoplasty System
FREMONT, Calif.–(BUSINESS WIRE)–Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced conformité européenne (CE) Mark for the company’s Coronary Lithoplasty® System for the treatment of calcified plaque in conjunction with stenting in patients with coronary artery disease. The Shockwave Medical Coronary Lithoplasty System is an innovative […]
NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation
LAKE FOREST, Calif.–(BUSINESS WIRE)–NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein one week ago in a patient suffering from severe tricuspid regurgitation stemming from two failed tricuspid annuloplasty rings that were unable to maintain the patient’s […]
Abiomed (ABMD) Introduces 3rd Generation Impella CP® Heart Pumps At SCAI 2017
DANVERS, Mass., May 09, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced the debut of the 3rd Generation Impella CP heart pump at the Annual meeting of the Society for Cardiovascular and Angiography Interventions (SCAI 2017) in New Orleans, LA. […]
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
MUNICH, April 27, 2017 /PRNewswire/ — ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a […]
LivaNova (LIVN) Takes Out Caisson Interventional in $72 Million Deal
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has acquired the remaining outstanding interests in Caisson Interventional, LLC (“Caisson”), in support of LivaNova’s strategic growth initiatives. Based in Maple Grove, Minn., Caisson is a privately held clinical-stage medical device company focused on […]
Quanterix To Discuss Precision Cardiovascular Medicine At World Medical Innovation Forum
LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, CEO and Executive Chairman at Quanterix, will join a distinguished panel of industry experts to discuss the state and future of precision cardiovascular medicine at the World Medical Innovation […]
Medtronic Launches Resolute Onyx (TM) Drug-Eluting Stent in US Following FDA Approval Becoming First DES Available in 4.5mm and 5mm Sizes
By GlobeNewswire Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S. DUBLIN – May 1, 2017 -Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) Drug-Eluting Stent (DES). […]



